20:06 , Apr 24, 2019 |  BC Extra  |  Financial News

Why Satsuma investors see room for another migraine therapy

While a new class of drugs has captured most of the attention around migraine treatments, Satsuma's investors believe there's room in the marketplace for a new formulation of an old drug. Satsuma Pharmaceuticals Inc. (South...
21:59 , Apr 22, 2019 |  BC Extra  |  Company News

FDA accepts BLA for Alder's migraine therapy for infusion

Alder said FDA accepted a BLA for eptinezumab to prevent migraine. The company, which submitted the BLA on Feb. 21, said it expects to receive a PDUFA date within 74 days following the submission. If...
20:38 , Apr 9, 2019 |  BC Extra  |  Company News

Management tracks: Cyclerion, Alkermes, Alder

A week after completing its spinout from Ironwood, Cyclerion has hired Andreas Busch as chief innovation officer. Busch was EVP, head of R&D and CSO at Shire plc and previously served as EVP, head of...
16:32 , Apr 5, 2019 |  BC Week In Review  |  Company News

Novartis, Amgen in legal battle over Aimovig collaboration

Almost one year after the launch of migraine therapy Aimovig erenumab-aooe, Novartis has filed a lawsuit alleging that its partner Amgen is trying to illegally back out of its deal, prompting Amgen to counter sue....
21:35 , Mar 18, 2019 |  BC Extra  |  Company News

Biohaven spends $105M for faster review of oral CGRP inhibitor

Biohaven bought a $105 million Priority Review voucher from GW Pharmaceuticals to expedite the entry of its oral migraine therapy into the CGRP inhibitor market. It plans to use the voucher on an NDA for...
01:33 , Mar 1, 2019 |  BC Week In Review  |  Clinical News

Alder submits BLA for migraine therapy, raises $130M in follow-on

After submitting its first BLA to FDA on Feb. 22, Alder BioPharmaceuticals Inc. (NASDAQ:ALDR) raised $130 million in a bumped-up follow-on late Feb. 27. Alder submitted the BLA for eptinezumab, a mAb against calcitonin-related gene...
00:52 , Jan 23, 2019 |  BC Extra  |  Company News

Management tracks: GSK, A*STAR, Moderna

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) said Philip Hampton will step down as chairman ahead of the pharma’s planned split of its consumer healthcare and innovative R&D businesses. The pharma said it has started to search for...
00:08 , Jan 23, 2019 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Migraine In vitro and rat studies identified a mAb against the ADCYAP1-derived peptides PACAP-38 and PACAP-27 that could help treat migraine. In vitro screening of B cell cultures of PACAP-38-immunized rabbits for mAbs that...
02:49 , Jan 5, 2019 |  BioCentury  |  Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
01:42 , Dec 13, 2018 |  BC Extra  |  Company News

Management tracks: Tamura reclaims CEO role at Sosei

Sosei Group Corp. (Tokyo:4565) said Peter Bains will step down as president and CEO and resign as director on Dec. 31. Executive Chairman, founder and former CEO Shinichi Tamura will replace Bains, effective Jan. 1....